Clinical
Research & Trials

We are committed to offering our patients the latest developments in medicine while also providing the highest quality patient care. One of the ways we accomplish this goal is through clinical trials. Clinical trials are at the heart of all medical advances, offering new and innovative solutions to patients that are not widely available to the public.
patient-resources

Current Clinical Studies

CCM Therapy

CCM therapy is an investigational advanced treatment option currently available through clinical trials, using an implanted device designed to help improve heart function and manage heart failure symptoms.

Integra-D

This clinical trial investigates the safety and effectiveness of a new type of implantable defibrillator (ICD) called the Integra-D, a smaller and more efficient ICD designed to improve the quality of life for people with heart failure.

Impulse Dynamics

For this trial, SWCVA is collaborating with pioneering developer Impulse Dynamics. Together, we are transforming care through groundbreaking technologies like the Optimizer® Smart System and Torus2 stent graft.

Our Research

Bay Area Cardiology physicians have been participating in clinical research since 1992. 
Since then we have been involved in over 90 studies both nationally and internationally. Through patient-oriented research Bay Area Cardiology seeks to improve treatments and outcomes.
Bay Area Cardiology physicians have been participating in clinical research since 1992. Since then, we have been involved in over 120 studies both nationally and internationally. Through patient-oriented research Bay Area Cardiology seeks to improve treatments and outcomes.
Bay Area Cardiology is proud of its dedicated team of four full time professionals who are experienced at coordinating trials and maintaining a high standard of quality and performance.

Our experience with clinical trials includes registries, investigational medications, FDA post market approved drugs, coronary stents, peripheral stents, carotid stents, pacemakers, Bi-V and AICD devices.

We participate in both office and hospital based studies that cover a wide variety of cardiac and vascular medicine and treatments.

Our current enrolling clinical trials include treatment of:
- Hyperlipidemia (Both elevated LDL or LPa)
- Heart Failure
- Non-Valvular Atrial Fibrillation
- Peripheral Arterial Disease
- Acute MI (Heart attack)
- COPD



Examples of Our Clinical Studies:

patient-information

ADAPTA (Medtronic)

A randomized trial to compare single-chamber atrial (AAl) and Dual-chamber (DDD) pacing in patients with Sick Sinus Syndrome

– Ranked #1 out of 100 sites
– PI: Dr. Mester

patient-information

RELY (Boehringer Ingelheim)

Randomized Evaluation of Outcomes of Long Term Anticoagulant therapy.

– Ranked #9 out of 952 sites
– PI: Dr. Khant
patient-information

RATE (St. Jude Medical)

Registry of AT/AF Episodes in the CRM Device Population

– Ranked #5 out of 19 sites
– PI: Dr. Betzu
patient-information

PREDETERMINE (NIHL)

Markers of Sudden Cardiac Death Registry

– Ranked #6 out of 105 sites
– PI: Dr. Bugni
patient-information

TRANSLATE (DCRI)

Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome

– Ranked #55 out of 233
– PI: Dr. Rodriguez

IMPROVE-IT (Merck/Schering Plough)

Improved Reduction of Outcomes: Vytorin Efficacy International Trial

– Ranked #67 out of 359 sites
– PI: Dr. Betzu

CAMELLIA (Eisai)

A Randomized, Double-blind, Placebo-controlled, Parallel- group Study to Evaluate the Long-term Treatment with BELVIQ (lorcaserin HCL) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

– Ranked #3 out of 400 sites
– PI: Dr. Chokshi

Patient REVEAL (Merck/Oxford University)

HPS 3/ TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease.

– Ranked #61 out of 151 sites
– PI: Dr. Khan

PAH (Actelion)

Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program

– Ranked #22 out of 71 site
– PI: Dr. Dewhurst

ST SEGMENT (Medtronic)

Virtuoso Implantable Cardioverter Defibrillator ST Segment Algorithm

– Ranked #4 out of 24 sites
– PI: Dr.Mester

1160.128 (Boehringer Ingelheim)

A prospective, open-label study evaluating the efficacy of two management strategies (pantoprazole 40 mg q a.m. and taking Pradaxa with food (within 30 minutes after a meal)) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa 150 mg b.i.d. or 75 mg b.i.d. for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).

– Ranked #4 out of 26 sites
– PI: Dr. Khant

EFFECT-AF (Laser)

An Atrial Fibrillation treatment registry

– Ranked #12 out of 54
– PI: Dr. Perzanowski